Clinicopathological Features and Survival Outcomes of Colorectal Medullary Carcinoma: a Retrospective Study Based on the SEER Database

Lu Han,Yaping Zhang,Qun Zhang,Jing Hu,Li,Xiao Shi,Zhou Ding,Xiaoping Qian

DOI: https://doi.org/10.21203/rs.3.rs-2392043/v1

2022-01-01

Abstract:Abstract Object: To investigate the relationship between clinicopathological characteristics and survival prognosis of patients with colorectal medullary carcinoma (MC), and to compare the prognostic differences between MC, colorectal neuroendocrine carcinoma (CRC-NEC) and colorectal neuroendocrine tumor (CRC-NET), in order to provide a more targeted treatment plan for colorectal cancer (CRC) and provide an evidence-based basis for evaluating the prognosis of patients. To provide a more targeted treatment plan for colorectal cancer (CRC) and an evidence-based basis for evaluating patient prognosis. Methods: From 2010 to 2019, 495 patients with pathological diagnosis of MC, 2440 patients with CRC-NEC and 9626 patients with CRC-NET were collected from the SEER database. The differences in clinicopathological characteristics between the groups were compared and the corresponding survival curves were plotted. 1:1 Propensity Score Matching (PSM) was used to eliminate the differences in baseline information between the groups, and the Kaplan-Meier method and log-rank test were used to compare the survival rates of patients in different groups. Cox regression models were developed to assess the predictive value of potential predictors for patients' clinical outcomes. Results: A total of 495 patients with MC were included in this study, and Multivariate analysis revealed that AJCC stage III+IV (HR=2.514, 95%CI: 1.796-3.519, P<0.001), positive tumor deposition (HR=1.723, 95%CI: 1.187-2.499, P=0.004), undergoing surgical treatment (HR=0.16, 95%CI: 0.065-0.393, P<0.001) and receiving chemotherapy (HR=2.328, 95%CI: 1.538-3.523, P<0.001) were potential independent risk factors on OS in MC patients. In addition, the OS and CSS of MC patients were significantly better than those of NEC patients before and after PSM matching (P<0.05); and the OS of MC patients was also better than that of CRC-NET patients before PSM matching (P<0.05), while the OS of MC patients was not significantly different from that of CRC-NET patients after PSM matching (P>0.05). Conclusion: MC has unique clinicopathological features and its prognosis is better than that of CRC-NET and CRC-NEC.